Piramal Pharma Solutions Thursday said it has invested USD 10 million (around Rs 69 crore) to expand its high-potency active pharmaceutical ingredients (HPAPIs) capability in its Riverview facility in the US.
The new wing at the Riverview site is dedicated to the production of HPAPIs with low occupational exposure levels (OELs), Piramal Pharma Solutions said in a statement.
Piramal Pharma Solutions Chief Executive Officer Vivek Sharma said: "We are one of only a few companies in the contract development and manufacturing market that have the capability to produce HPAPIs at such low OELs."
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app